ClinPGx Blog (Page 32)

Sign in Subscribe

More issues

Live from PSB: Phil Bourne from the NIH

Aloha! PharmGKB is at the Pacific Symposium on Biocomputing (PSB) on the big island of Hawaii. We will broadcast Phil Bourne's talk on "NIH Big Data from Science to Careers" over the web via the BlueJeans teleconferencing system. There will also be a phone number to

December SNPits Summary

In the December issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, a recent study by Lee, et al. entitled "DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment" is reviewed. The authors find a statistically significant association between DPYD*2A and rs67376798

CPIC Term Standardization

CPIC (Clinical Pharmacogenetics Implementation Consortium) is leading an effort to standardize terms for clinical pharmacogenetic tests. The goal of the project is to create standardized terms to be used in CPIC guidelines (specifically Tables 1 and 2) and in the larger pharmacogenetics community. A list of phenotype term options based

Annotated PMDA drug labels now available on PharmGKB

PharmGKB now has annotated drug labels available from the Pharmaceutical and Medical Devices Agency (PMDA), Japan. The PMDA is a regulatory agency responsible for scientific reviews for the approval of drugs or medical devices, as well as safety monitoring after approval. The PMDA website provides PDF copies of package inserts

November SNPits Summary

The November issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, is out. This issue contains a summary of a recent paper by Nicholson and Formea in Clinical Chemistry that discusses implementing CPIC guidelines for CYP2D6 and codeine. The authors highlight some of the difficulties that may arise

PharmGKB VIP Summary for CYP4F2 published in Pharmacogenetics and Genomics

The PharmGKB Very Important Pharmacogene (VIP) summary describing important pharmacogenetic variants in CYP4F2 was recently published by Pharmacogenetics & Genomics. Cytochrome p450, family 2, subfamily F, polypeptide 2 (CYP4F2) catalyzes the oxidation of the terminal carbon of the side chains of vitamin K, vitamin E, arachidonic acid (AA), and leukotriene

Clinical evidence support for biomarkers on FDA-approved drug labels

A recent article by Wang et al. in JAMA Internal Medicine reviews the clinical evidence support found on FDA-approved drug labels that are listed on the FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling. The authors found that many labels on the list did not contain, or reference,

ClinGen's GenomeConnect Patient Portal Launches

The NIH-funded Clinical Genome Resource (ClinGen) project has launched its patient portal at GenomeConnect. This site provides a patient registry for those who have already had or are contemplating genetic testing, or have family members who have been tested. It is open to the public for enrollment. Once a personal

New pathway: Ibuprofen Pharmacodynamics

We have added a new pathway: ibuprofen PD pathway to PharmGKB's pathway collections. Ibuprofen is a traditional non-steroidal anti-inflammatory drug (NSAID) widely used for its analgesic, anti-inflammatory, and anti-pyretic properties. The main mechanism of action of ibuprofen is the non-selective, reversible inhibition of the cyclooxygenase enzymes COX-1 and

PharmGKB Wikipedia page

PharmGKB now has a Wikipedia page. The page provides an overview of our purpose, as well as the types of content available on the website. PharmGKB would like to invite the community to add to the page, or email us suggestions for what you think would be useful to include.